Mentions
Extended reach
Total likes
Video views
AI synopsis
The collective discussions emphasize the profound impact of the DAPA-CKD trial, with posts describing it as 'transformative' and 'practice-changing,' supported by phrases like 'solid evidence' and 'significant benefit,' reflecting both deep engagement and high interest. The tone highlights the trial’s implications for treatment guidelines and broad clinical impact, evidenced by references to guidelines, mechanisms, and trial results.
Most discussions highlight strong support and positive acknowledgment of the study's findings, emphasizing its significance in improving kidney and cardiovascular outcomes.
Posts demonstrate a high level of interest, often diving into details about trial results, mechanism discussions, and clinical implications.
Multiple comments reference specific trials, guidelines, and clinical practices, indicating deep engagement and thoughtful consideration.
The overall consensus recognizes the publication as a practice-changing study that influences current treatment strategies for CKD, especially in non-diabetic populations.
We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chronic Kidney Disease
2020: DAPA-CKD Dapagliflozin testes in pts with eGFR between 25 and 75 mL/min, regardless of diabetes. Result: improved outcomes in pts taking dapagliflozin, including less dialysis and decreased death from any cause. https://t.co/FgpPwu23bm 14/20
Dapagliflozin in Patients with CKD Among patients with CKD regardless of diabetes, risk of a composite of a sustained decline in GFR of at least 50%, end-stage kidney disease, or death from renal or CV causes was significantly lower with dapagliflozin https://t.co/GKSoGs1Ift https://t.co/CmgomNZgrP
This flowchart, adapted from NICE Guidelines (July 2025), outlines the eligibility criteria for Dapagliflozin in patients with Chronic Kidney Disease (CKD): https://t.co/L4gQE5Smzo https://t.co/krwf61qruM
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/3ZfOcTU5YL
そろそろVisual Abstractでも作ってみようかということで、日本の伝統デジタル工芸の一つでもあるエクセル方眼紙（+懐かしの創英角ポップ体）を用いて作ってみました。ご査収ください。 https://t.co/WEWuUgDMjf https://t.co/eRD68OELDM
This Harvard Medical School Continuing Education video explores how SGLT2 inhibitors like canagliflozin and dapagliflozin protect the kidneys, review key trial findings, and discuss updated guidelines, highlighting…
Explore the latest advancements in kidney care from American Kidney Week 2024, highlighting new medications, dialysis technologies, and stem cell research aimed at reducing proteinuria and improving kidney function.
Ryker Black reveals findings from a double-blind trial that identifies a revolutionary anti-aging pill, influencing aging processes significantly. The study highlights empagliflozin's positive impact on cardiovascular…
Diabetes often leads to kidney damage and proteinuria. This video explains the four scientifically proven medicines shown to reduce protein leak in urine and protect kidney health, supported by recent clinical research.
Prof. Johannes Mann discusses target blood pressure values for individuals with elevated cardiovascular risk based on the STEP trial presented at the European Society of Cardiology. The conversation interprets results…
In this episode, Koyal and Kenar recap essential knowledge about IgA nephropathy (IgAN) for board examinations and treatment decisions. Emphasizing a recent study, they reveal that methylprednisolone reduces serious…
Dapagliflozin and finerenone can be combined to protect the kidneys and heart. This video explains how these medications work and their benefits for chronic kidney disease and type 2 diabetes patients, including those…
In this podcast, John Mandrola MD discusses SGLT2 inhibitors, their effects on chronic kidney disease, and highlights significant trial outcomes showing a 30% lower risk of severe kidney issues with Canagliflozin. A…
RT @drsthanus: This flowchart, adapted from NICE Guidelines (July 2025), outlines the eligibility criteria for Dapagliflozin in patients wi…
RT @drsthanus: This flowchart, adapted from NICE Guidelines (July 2025), outlines the eligibility criteria for Dapagliflozin in patients wi…
RT @drsthanus: This flowchart, adapted from NICE Guidelines (July 2025), outlines the eligibility criteria for Dapagliflozin in patients wi…
RT @drsthanus: This flowchart, adapted from NICE Guidelines (July 2025), outlines the eligibility criteria for Dapagliflozin in patients wi…
RT @drsthanus: This flowchart, adapted from NICE Guidelines (July 2025), outlines the eligibility criteria for Dapagliflozin in patients wi…
RT @drsthanus: This flowchart, adapted from NICE Guidelines (July 2025), outlines the eligibility criteria for Dapagliflozin in patients wi…
RT @drsthanus: This flowchart, adapted from NICE Guidelines (July 2025), outlines the eligibility criteria for Dapagliflozin in patients wi…
This flowchart, adapted from NICE Guidelines (July 2025), outlines the eligibility criteria for Dapagliflozin in patients with Chronic Kidney Disease (CKD): https://t.co/L4gQE5Smzo https://t.co/krwf61qruM
RT @drbennisahmed: Dapagliflozin in Patients with CKD Among patients with CKD regardless of diabetes, risk of a composite of a sustained…
RT @drbennisahmed: Dapagliflozin in Patients with CKD Among patients with CKD regardless of diabetes, risk of a composite of a sustained…
RT @drbennisahmed: Dapagliflozin in Patients with CKD Among patients with CKD regardless of diabetes, risk of a composite of a sustained…
RT @drbennisahmed: Dapagliflozin in Patients with CKD Among patients with CKD regardless of diabetes, risk of a composite of a sustained…
RT @drbennisahmed: Dapagliflozin in Patients with CKD Among patients with CKD regardless of diabetes, risk of a composite of a sustained…
RT @drbennisahmed: Dapagliflozin in Patients with CKD Among patients with CKD regardless of diabetes, risk of a composite of a sustained…
RT @drbennisahmed: Dapagliflozin in Patients with CKD Among patients with CKD regardless of diabetes, risk of a composite of a sustained…
Dapagliflozin in Patients with CKD Among patients with CKD regardless of diabetes, risk of a composite of a sustained decline in GFR of at least 50%, end-stage kidney disease, or death from renal or CV causes was significantly lower with dapagliflozin https://t.co/GKSoGs1Ift https://t.co/CmgomNZgrP
Original article: https://t.co/h2HeeQa2P9
Referencia: 1.Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med [Internet]. 2020;383(15):1436–46. Disponible en: https://t.co/tkE2YgNxSS
Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty https://t.co/cMbuYHmaVu
対象論文 ☞ https://t.co/kT2U8E3z5Z
RT @hvanspall:
Dapagliflozin in Patients with Chronic Kidney Disease | New England Journal of Medicine https://t.co/l2KRalzqCM
RT @EndoDialogues: 2020: DAPA-CKD Dapagliflozin tested in pts with eGFR between 25 and 75 mL/min, regardless of diabetes. Result: impro…
2020: DAPA-CKD Dapagliflozin tested in pts with eGFR between 25 and 75 mL/min, regardless of diabetes. Result: improved renal outcomes in those assigned to dapagliflozin, including less dialysis and, now unsurprisingly, decreased death from any cause. https://t.co/FgpPwu23bm
Open Access UCL Research: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial https://t.co/UUCmdskFSd
24a) @goKIDIGO 3.7 Sodium-glucose cotransporter-2 inhibitors (#SGLT2i) Some of the trials that support the use of SGLT2i in this population are: #CREDENCE
24a) @goKIDIGO 3.7 Sodium-glucose cotransporter-2 inhibitors (#SGLT2i) Some of the trials that support the use of SGLT2i in this population are: #CREDENCE
How does #Zibotentan and #Dapagliflozin combination therapy compare to a Dapagliflozin standard? Find out today with our detailed, free to access slide deck: https://t.co/xW9zJTuVSn
Stay at the forefront of cardiometabolic treatments with our detailed slide materials on the #ZENITH-CKD Phase 2b trial from Heerspink et al. https://t.co/xW9zJTuVSn
The latest publication by Heerspink et al. sought to investigate the 12-week efficacy of #Zibotentan and #Dapagliflozin combination therapy. Access the results in our full slide deck summary today! https://t.co/xW9zJTuVSn
Want the latest insights from the #ZENITH-CKD Phase 2b trial? Then head on over to the #CMF where we have just posted our latest detailed slide decks: https://t.co/xW9zJTuVSn https://t.co/OtXBShmEJG
New Research: Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial: Sodium glucose cotransporter 2 (SGLT2) inhibitors have both glucose-lowering and diuretic effects. We… https://t.co/KhbhYmv1GK #medicalcare #clinical #pathology
RT @NDTsocial:
RT @ioana_nussa: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-C…
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/g24svQEfeH
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/FheJthLpBV
RT @FormigaFrancesc: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENI…
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/4gYS1TpBFp
[Articles] Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial https://t.co/xyYa9eTvI5
RT @ValleAlfonso: #CaReMe
RT @kdjhaveri: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD…
RT @kdjhaveri: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD…
RT @kdjhaveri: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD…
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/RMqAESFvi3
RT @kdjhaveri: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD…
RT @kdjhaveri: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD…
RT @kdjhaveri: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD…
RT @kdjhaveri: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD…
RT @kdjhaveri: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD…
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet...
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/3ZfOcTU5YL
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/29cbg3dXJc
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/29cbg3dXJc
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/29cbg3dXJc
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/29cbg3dXJc
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/29cbg3dXJc
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/29cbg3dXJc
RT @CristobMorales: https://t.co/yz8dk2nUhY Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chron…
Open Access UCL Research: Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial https://t.co/GDclSpLTM5
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial https://t.co/A54eCLNhU3 https://t.co/2Tav5zEfYN
RT @CristobMorales: https://t.co/yz8dk2nUhY Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chron…
RT @CristobMorales: https://t.co/yz8dk2nUhY Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chron…
RT @CristobMorales: https://t.co/yz8dk2nUhY Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chron…
RT @CristobMorales: https://t.co/yz8dk2nUhY Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chron…
https://t.co/yz8dk2nUhY Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. “Zibotentan combined with dapagliflozin reduced https://t.co/BjTKbWPgXn
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/AZAkyp9KRt
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet https://t.co/ALg5LBQuCZ
[Articles] Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial #science #publication #research #journal https://t.co/X0UlMOcXcp
[Articles] Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial #science #publication #research #publications https://t.co/d10J1SV1ee
Results of the ZENITH-CKD trial provide evidence of the safety and efficacy profile of combination zibotentan plus dapagliflozin in patients with chronic kidney disease. https://t.co/eIPnPnYWdj #KidneyWk #Nephrology
Nephroprotectino at the ZENITH? Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease reduces albuminuria - with long-term renal outcome still unknown. https://t.co/B37MIMhegH
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
RT @walinjom: What is the cut-off eGFR to give dapagliflozin, in patients with Chronic kidney disease and diabetes? A SGLT2 inhibitor (can…
53b) ... from #renal or #CVcauses was significantly lower with #dapagliflozin than with placebo #VisualAbstract by @whatsthegfr https://t.co/XS7XmyrYmi https://t.co/w5kIcgoki4
@digidigidaisy ここで言う「腎保護」とは 推算糸球体濾過量（GFR）の維持を指しており、 SGLT2阻害薬投与群でプラセボ群より 「GFR低下の発生リスク」が有意に低いそうです。 https://t.co/1HHDIdpSpb また、尿管結石については SGLT2阻害薬投与により 尿管結石が出来にくくなるとの報告もあります。
15/ For more details on the data, check out the links below:
@DrPeterWeeks1 @MKeech2 @DrGoblin3 I think the NICE tech appraisal was based on the DAPA-CKD trial. https://t.co/EFp28VnhbE
5/ DAPA-CKD and EMPA-KIDNEY investigated the efficacy and safety of #SGLT2 inhibitors in patients with #CKD with and without #T2D DAPA-CKD:
@pabonnet @FaconFlorian @exercer_Revue J'ai pas trop insisté sur le blog c'est vrai : https://t.co/IaSh29MHx3 pour la dapa et https://t.co/lFciA4MLTa pour l empa. Avantage à la dapa qui réduit en plus des évènements rénaux, les événements CV et la mortalité
RT @cardiomet_CE: 19e) #DAPA_CKD
RT @cardiomet_CE: 19e) #DAPA_CKD
19e) #DAPA_CKD
DAPA-CKDはESRDでも有意に抑制しているようなので、現在はそこまでの有効性を示すことが必要なのかもしれない。 https://t.co/dHIE28Rozn https://t.co/ZBcrNlT1jS
RT @ckd_ce: 19e) #DAPA_CKD
19e) #DAPA_CKD
Odličan osvrt na
@jurian19 @egm_1025 @jimenadegortari https://t.co/4S37hSFxGq El tipo de medicamentos que ha estudiado el dr Correa son quizá los de mayor impacto tanto a nivel renal y cardiovascular
RT @CMNO_MedInt: Estudio clínico aleatorizado: Dapagliflozina en pacientes con enfermedad renal crónica (estudio DAPA-CKD). Revista: @NEJM…
26) In #DAPA_CKD where ⅔ of patients had #T2D & had an #eGFR of 25-75 mL/min & median #UACR of 950 mg/g, #dapagliflozin reduced primary composite outcome (#ESKD, ⬇️eGFR at least 50%, CV/renal death) across all subgroups.
Dapagliflozin in Patients with Chronic Kidney Disease https://t.co/Ex8e3JsuSQ
RT @ckd_ce: 26) In #DAPA_CKD where ⅔ of patients had #T2D & had an #eGFR of 25-75 mL/min & median #UACR of 950 mg/g, #dapagliflozin reduced…
26) In #DAPA_CKD where ⅔ of patients had #T2D & had an #eGFR of 25-75 mL/min & median #UACR of 950 mg/g, #dapagliflozin reduced primary composite outcome (#ESKD, ⬇️eGFR at least 50%, CV/renal death) across all subgroups.
RT @drdschwartzmd: Found that among patients with CKD, regardless of the presence or absence of diabetes, composite of sustained decline in…
Found that among patients with CKD, regardless of the presence or absence of diabetes, composite of sustained decline in eGFR of >=50%, ESKD, or death from renal or CV causes was significantly lower with dapagliflozin than with placebo https://t.co/cYom3L4Jtg
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @edgarvlermamd: DAPA-CKD: Among patients w/ CKD, regardless of presence/ absence of diabetes, the risk of a composite of a sustained dec…
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ValleAlfonso: #CaReMe
RT @ckd_ce: 7) This recommendation is based on strong evidence that #SGLT2i reduce #CKD progression, #HF, and #ASCVD risk in patients with…
RT @mendesthiagob: 2020: DAPA-CKD Dapagliflozin testes in pts with eGFR between 25 and 75 mL/min, regardless of diabetes. Result: improve…
2020: DAPA-CKD Dapagliflozin testes in pts with eGFR between 25 and 75 mL/min, regardless of diabetes. Result: improved outcomes in pts taking dapagliflozin, including less dialysis and decreased death from any cause. https://t.co/FgpPwu23bm 14/20
RT @ckd_ce: 15) These changes are driven largely by findings of new trials, including the #DAPA_CKD trial (which provided clear evidence of…
RT @ckd_ce: 8) These trials enrolled pts w/ #albuminuria: #CREDENCE: ACR >/=300 mg/g #DAPA_CKD: ACR >/=200 mg/g & showed significant benefi…
RT @ckd_ce: 7) This recommendation is based on strong evidence that #SGLT2i reduce #CKD progression, #HF, and #ASCVD risk in patients with…
今のところフォシーガのRCTがあるけど、これだけ読むとかなり有効な印象。死亡率改善のため早期終了になっている。 ただ他の研究がまだ出ていないのと、有害事象もまだ気になるので、プライマリ・ケア医は様子見の段階でよいと思う。 https://t.co/VCcA0O4GeO
RT @ckd_ce: 7) This recommendation is based on strong evidence that #SGLT2i reduce #CKD progression, #HF, and #ASCVD risk in patients with…
RT @ckd_ce: 15) These changes are driven largely by findings of new trials, including the #DAPA_CKD trial (which provided clear evidence of…
15) These changes are driven largely by findings of new trials, including the #DAPA_CKD trial (which provided clear evidence of efficacy and safety for #dapagliflozin in patients with #eGFR >/= 25 and #ACR >/= 200 mg/g) DAPA-CKD:
8) These trials enrolled pts w/ #albuminuria: #CREDENCE: ACR >/=300 mg/g #DAPA_CKD: ACR >/=200 mg/g & showed significant benefit for composite outcomes/EPs:
7) This recommendation is based on strong evidence that #SGLT2i reduce #CKD progression, #HF, and #ASCVD risk in patients with #T2D and CKD #VisualAbstract by @brendonneuen @whatsthegfr #CREDENCE
RT @cardiomet_CE: 6) This is regardless of whether patients do or do not have #diabetes, according to the results of the #DAPA-CKD clinical…
6) This is regardless of whether patients do or do not have #diabetes, according to the results of the #DAPA-CKD clinical trial (
6) This is regardless of whether patients do or do not have #diabetes, according to the results of the #DAPA-CKD clinical trial (
35b) See https://t.co/Y9SbbOWymI
35b) See https://t.co/mIoaeMh9K8
RT @ckd_ce: 36) Yes . . . we already have #DAPA-CKD: in pts w/CKD, ➕or➖diabetes, risk of composite of sustained⬇️eGFR of at least 50%/ESKD/…
36) Yes . . . we already have #DAPA-CKD: in pts w/CKD, ➕or➖diabetes, risk of composite of sustained⬇️eGFR of at least 50%/ESKD/death from renal/CV causes was significantly lower with dapagliflozin (vs placebo) #VisualAbstract by @whatsthegfr
https://t.co/O11NQ8bQF9 Fig3 ホンマや
https://t.co/exQY9BMWpY 平均61歳、平均BMI30
Dapagliflozin in Patients with Chronic Kidney Disease | NEJM https://t.co/K0IBf3huGM
昨日の投稿、多くの方にご覧いただき、ありがとうございます
DAPA-DKDはeGFR30 ml/分/1.73m2未満が14.5％。 こいつのサブ解析を待てばいいのか。 https://t.co/g3ESEeUQyy
RT @q0_0_: DAPA-CKD trial, NEJM 2020 慢性腎臓病患者(eGFR25-75, 尿アルブミン200-5000mg/gCr)に対するdapaglifrozin 10mgの腎保護効果を評価したランダム化二重盲検比較試験において、糖尿病群でも非糖尿病群…
DAPA-CKD trial, NEJM 2020 慢性腎臓病患者(eGFR25-75, 尿アルブミン200-5000mg/gCr)に対するdapaglifrozin 10mgの腎保護効果を評価したランダム化二重盲検比較試験において、糖尿病群でも非糖尿病群でもdapaglifrozinによるGFR低下率≧50%の発症抑制効果が確認されました。 https://t.co/HQ4lkf4deE https://t.co/NEfA1z2R9A
RT @iforumrx: The recently published
The recently published
@DrGiovanniD https://t.co/Q051acgyvK
@rolosanchez77 @effects It does. DAPA-CKD trial. https://t.co/PXv9nzGj0R mechanism is still up for debate. Activation of tubuloglomerular feedback leading to aff art vasoconstr and fall in intraglomerular HTN is a potential one. Increase in renal mass has also been postulated
Se une a la buena noticia que supuso el estudio (https://t.co/OpUEN2lEOo) que demuestra su beneficio en pacientes con insuficiencia renal (filtrado 25-75 ml/min 1.73 m2 y albúmina/creat 200-5000. ↓44% del evento combinado.
RT @HanCardiomd: Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived Results of…
Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived Results of the DAPA-CKD trial were published in the New England Journal of Medicine (https://t.co/xbxdYWhbMI) https://t.co/gApEjFWiLV @ehj_ed @ESC_Journals @HFSA https://t.co/r77dZzs8Ch
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
RT @SSCP_KSA: We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chr…
We are happy to announce the upcoming Internal Medicine PSN Journal Club. Article Title: Dapagliflozin in Patients with Chronic Kidney Disease
Dapagliflozin in Patients with Chronic Kidney Disease https://t.co/fljo03WLzl DMの有無に関わらず、
RT @pinacol: そろそろVisual Abstractでも作ってみようかということで、日本の伝統デジタル工芸の一つでもあるエクセル方眼紙（+懐かしの創英角ポップ体）を用いて作ってみました。ご査収ください。 https://t.co/WEWuUgDMjf https:…
そろそろVisual Abstractでも作ってみようかということで、日本の伝統デジタル工芸の一つでもあるエクセル方眼紙（+懐かしの創英角ポップ体）を用いて作ってみました。ご査収ください。 https://t.co/WEWuUgDMjf https://t.co/eRD68OELDM
@DrFlashHeart @kidney_boy agreed w/ you re: the Research in Social Justice Award- that is a touching story & inspiring initiative, although the Article of the Year_has_to be the @NEJM DAPA-CKD study: https://t.co/3QY2fYQzWw the practice-changing paper of all-time, #SGLT2ization cc: Dr. @ChristosArgyrop
元論文はNEJMよりこちら https://t.co/zvVbGduoQy
Dapagliflozin in Patients with Chronic Kidney Disease https://t.co/u7xwbyGqyc
Dapagliflozin is demonstrating solid evidence for use in CKD patients (with or without T2DM) based on the results of the recently published DAPA-CKD trial, which is summarized below! Link to full article included here: https://t.co/w0B9qPHq1c #pharmacy #evidencebasedmedicine https://t.co/lY8SxUxpuB
#Dapagliflozin in Patients with Chronic Kidney Disease @NEJM https://t.co/BlHoUVHtHc
RT @NephJC: Tonight, we are discussing the DAPACKD from @NEJM https://t.co/lXMJYGkpk4 #NephJC
Tonight, we are discussing the DAPACKD from @NEJM https://t.co/lXMJYGkpk4 #NephJC
Tonight, we are discussing the DAPACKD from @NEJM https://t.co/Z45PS6fN8H #NephJC
Dapagliflozin in Patients with Chronic Kidney Disease https://t.co/WAMzQqnkie
RT @NephJC: Tonight, we are discussing the DAPACKD from @NEJM https://t.co/Z45PS6fN8H #NephJC
RT @NephJC: Tonight, we are discussing the DAPACKD from @NEJM https://t.co/Z45PS6fN8H #NephJC
Tonight, we are discussing the DAPACKD from @NEJM https://t.co/Z45PS6fN8H #NephJC
Erfolgreich gegen die CKD-Progression! Dapagliflozin reduzierte das Risiko für eine Verschlechterung der Nierenfunktion, Dialysepflicht u. Tod um 39 % gegenüber Placebo und schützte die Nieren auch bei Nichtdiabetikern. https://t.co/TBhs2woouO
Dapperly Gliding into the Nondiabetic Arena https://t.co/WrrdLb9th0 @priti899 #NephJC @deniise_am Dapagliflozin in Patients with Chronic Kidney Disease https://t.co/yPLUO6CyxK #DAPA-CKD #NEJM https://t.co/b8c4xmyCxp
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024816
sglt2と腎予後 https://t.co/2fQ5Xi8kT3
【RCT】eGFR25-75mL/min/1.73m^2で尿中アルブミン/クレアチニン比200-5000のCKD患者へのダパグリフロジン投与は、プラセボ投与と比較して、複合評価項目（eGFRの少なくとも50%の持続的な低下、末期腎疾患等）のリスクを2型糖尿病の有無にかかわらず減少させた。 #ペ読 https://t.co/WEWuUgDMjf
Dapagliflozin in Patients with Chronic Kidney Disease. https://t.co/apXNL2s0CK
Dapagliflozin in Patients with Chronic Kidney Disease. https://t.co/FjNyCcHm8T https://t.co/MHlHJqJUw7
Our next renal grand rounds on Tuesday sept 29 4pm EST will be exclusive on DAPA-CKD by David Wheeler all the way from the UK via zoom. https://www.nejm.org/doi/full/10.1056/NEJMoa2024816
C